Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells $590,600.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Stephen Feider also recently made the following trade(s):

• On Tuesday, December 2nd, Stephen Feider sold 1,427 shares of Beta Bionics stock. The stock was sold at an average price of $29.34, for a total value of $41,868.18.

Beta Bionics Trading Up 0.3%

BBNX stock opened at $31.49 on Thursday. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $32.71. The firm has a 50-day moving average of $29.32 and a two-hundred day moving average of $22.17. The firm has a market capitalization of $1.39 billion and a PE ratio of -7.21.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $27.25 million for the quarter, compared to analyst estimates of $23.92 million. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BBNX. Robert W. Baird set a $28.00 price target on Beta Bionics in a report on Tuesday, December 16th. Piper Sandler reaffirmed an “overweight” rating and set a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Bank of America increased their price target on shares of Beta Bionics from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group raised their price target on shares of Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Beta Bionics in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.70.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BBNX. Corebridge Financial Inc. bought a new stake in Beta Bionics during the first quarter worth approximately $79,000. Divisadero Street Capital Management LP acquired a new stake in shares of Beta Bionics in the second quarter worth $13,817,000. Alyeska Investment Group L.P. acquired a new stake in shares of Beta Bionics in the first quarter worth $918,000. Goldman Sachs Group Inc. bought a new stake in shares of Beta Bionics during the 1st quarter worth $715,000. Finally, Invesco Ltd. acquired a new position in Beta Bionics in the 1st quarter valued at $202,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.